need to minimize the risks of misuse and abuse, according to Dr. Passik. In "A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain," Charles Argoff, M.D., and Daniel Silvershein, M.D., both from the Department of Neurology, Albany Medical College
, N.Y., write that management of chronic non-cancer pain, for example, requires comprehensive assessment of each patient; the establishment of a structured treatment regimen or program; ongoing reassessment of the pain condition and the response to therapy; and a continual appraisal of the patient's adherence to the treatment. Their colleague, Dr. Smith, stresses the importance of understanding the metabolism of opioids in individual patients.
Keen awareness by family and friends of potential addiction is crucial for physicians and other health care providers, not to mention the general public, who might be at risk, according to "Chemical Dependency and the Physician" by Keith Berge, M.D., Department of Anesthesiology, Mayo Clinic; Marvin Seppala, M.D., Hazelden Foundation, Center City, Minn.; and Agnes Schipper, J.D., Mayo Clinic Legal Department. Especially important is that family, friends and co-workers of health care providers confront any suspected addiction and abuse because of the potential harm that might befall the individual and his or her patients. Health care facilities should have written policies and procedures in place to assist when these highly emotionally charged situations involving health care providers occur, Dr. Berge and his colleagues write. Long-term recovery and sobriety can be achieved with appropriate treatment, aftercare and monitoring, they add.
New opioid formulas designed to minimize abuse are now in late-stage development and could help, Dr. Passik says. These drugs are chemically designed to diminish euphoric effects, thus possibly reducing problematic use. For now, responsibility coupled with expertise, inPage: 1 2 3 4 Related medicine technology :1
. June 2009 Mayo Clinic Womens HealthSource Highlights Summer Skin Problems, Low Vision and Pilates2
. Alcon Commences Phase 2 Clinical Trial of NovaBays NVC-422 for Viral Conjunctivitis3
. BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis4
. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections5
. New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF6
. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases7
. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA2378
. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies9
. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis10
. West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial11
. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies